Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Warfarin

Preparation Calculator

Warfarin

Vitamin K antagonist (oral anticoagulant)

High YieldVTEAFINRAdult

Indication

DVT/PE β€’ Atrial fibrillation stroke prevention β€’ Mechanical heart valve (selected) β€’ recurrent VTE

At a glance

INDICATIONS (CORE USE)

Treatment/prevention of VTE; non-valvular AF stroke prevention; selected mechanical valves β€” **INR target indication-specific**.

ADULT DOSE (STANDARD)

Initiation 2–5 mg daily (often 5 mg if healthy outpatient); titrate to **target INR** (2–2.5 vs 2.5–3.5)

MAX DOSE

No fixed ceiling β€” limited by INR; rarely >15–20 mg/day in resistant cases with workup

Route

PO (IV rare same mg)

PEDIATRIC DOSE

Rare specialist use β€” weight-based initiation; pediatric hematology / cardiology only

Do not miss

Must-not-miss safety points

Major warning

- **Bleeding** β€” intracranial, GI, retroperitoneal; risk ↑ with supratherapeutic INR, falls, NSAIDs, uncontrolled HTN - Teratogenic β€” **pregnancy contraindicated** for warfarin (except rare mechanical valve scenarios β€” specialist) - Major drug–drug and drug–food interactions β†’ unpredictable INR

Indications

USE IF: Long-term anticoagulation when DOAC unsuitable, mechanical valves, severe renal failure on dialysis (often VKA), cost/access. AVOID IF: Pregnancy, inability to monitor INR, high bleed risk without reversible cause, concurrent interacting drugs without monitoring plan.

Primary

  • Treatment and secondary prevention of VTE
  • Non-valvular atrial fibrillation / flutter β€” stroke prevention when guideline-appropriate
  • Mechanical heart valves (especially older-generation aortic/mitral) per cardiology

Secondary

  • Post-MI with LV thrombus (selected)
  • Recurrent VTE on prior adequate DOAC (investigate)

Other

  • Antiphospholipid syndrome with thrombosis (often higher INR target β€” rheumatology)

Dosing

STANDARD (ADULT PO)

Typical maintenance 2–7 mg PO daily β€” entirely INR-driven

ADULT DOSE

Initiation: 2–5 mg daily; elderly/frail often lower start. Target INR **2.0–3.0** most VTE and NVAF; **2.5–3.5** mechanical mitral / selected APS. Overlap with parenteral anticoagulant until INR therapeutic β‰₯2 consecutive days (indication-specific).

PEDIATRIC DOSE

Specialist protocols only.

MAX DOSE

Dose capped by INR β€” not by mg alone.

Practical Note

Consistent vitamin K intake; avoid new NSAIDs/azoles/macrolides without INR plan; bridging peri-procedure per guideline.

Warnings

Clinical warnings

  • Necrosis/skin gangrene early course (protein C deficiency) β€” rare
  • Purple toe syndrome β€” rare
  • Heparin-induced thrombocytopenia overlap when bridging β€” separate HIT pathway

Adverse effects

  • Bleeding
  • bruising
  • elevated INR without bleed
  • GI upset
  • alopecia (rare)

Contraindications

  • **Active pathological / major bleeding** β€” stabilize/reverse per protocol before routine (re)start unless embedded in explicit reversal plan
  • **Upcoming invasive procedure** β€” **do not continue blindly**; document **hold/bridge/switch** with anesthesia/surgery when applicable
  • **Pregnancy** (warfarin teratogenicity) β€” **avoid** except rare specialist contexts; use alternate anticoagulation per OB
  • Pregnancy (except rare specialist-directed mechanical valve)
  • Hemorrhagic stroke or active pathological bleeding
  • Severe uncontrolled hypertension without plan

Drug interactions

  • **Interacting drug started or stopped** (antibiotic, amiodarone, azole, rifampin, etc.) β†’ **recheck INR within 48–72h** (sooner if bleeding or symptoms)
  • **Concurrent NSAID, added antiplatelet, or SSRI/SNRI** β†’ **bleeding risk ↑** β†’ **reassess necessity**; counsel melena/neuro red flags; **PPI** if co-use unavoidable and high GI risk
  • CYP2C9/3A4: amiodarone, azoles, macrolides, metronidazole, cimetidine, rifampin, carbamazepine
  • Antiplatelets, NSAIDs, SSRIs β†’ bleed risk
  • Broad-spectrum antibiotics β†’ INR swing

Special populations

Pediatrics

Rare specialist use β€” weight-based initiation; pediatric hematology / cardiology only

Pregnancy

**Pregnancy:** contraindicated (teratogenic) except rare valve scenarios β€” LMWH/ specialist. **

Lactation

** generally compatible at therapeutic doses β€” pediatric follow-up if concern.

Renal impairment

Warfarin not renally cleared β€” INR still primary; illness/AKI may alter INR via protein binding/interactions. **CrCl scaffold (FMBM β€” titrate to FDA/SFDA label + pharmacy / anticoagulation clinic):** - **CrCl β‰₯50** β†’ INR drives dose; no routine CrCl-based warfarin mg change (interactions dominate) - **CrCl 10–50** β†’ same β€” monitor INR closely if interacting drugs or illness alter binding/metabolism - **CrCl <10** / **dialysis** β†’ warfarin still used β€” **narrow therapeutic index**; more frequent INR with diet/illness changes

Hepatic impairment

Synthetic dysfunction β†’ baseline and frequent INR; often contraindicated in severe liver disease with coagulopathy.

Elderly

Lower initiation dose; fall risk + supratherapeutic INR β†’ bleed; polypharmacy interaction screen.

Administration

PO daily same time; IV only when PO impossible β€” same INR monitoring.

Monitoring

  • Monitor: - β€’ **INR >10, no bleed** β†’ **oral vitamin K** - β€’ **Any serious bleed** β†’ **4F-PCC + IV vitamin K immediately** - **Escalation β€” minor bleed:** **Hold** + **PO/SQ vitamin K** per protocol β€” escalate if worsening - **Escalation β€” heparin overlap:** **β‰₯5 days** parenteral heparin AND INR **therapeutic β‰₯24h** before stopping heparin - **Escalation β€” Hb ↓ without source:** Investigate bleed; **peri-procedure** β†’ bridge only if risk warrants - **Starting warfarin for acute VTE** β†’ **parenteral overlap** when indicated β€” **do not stop parenteral prematurely** per guideline - **Low-risk AF elective surgery** β†’ **avoid routine bridging** β€” use thromboembolic risk stratification - INR at initiation every **1–4 days** until stable then extend interval - Peri-procedure: bridging only when thromboembolic risk warrants β€” not routine for all low-risk procedures
  • Recheck: - **What to check + when:** **INR** β€” **48–72h** after dose change, illness, or interacting drug start/stop; **stable** outpatients typically **every 4–12 weeks** per clinic/guideline - **Escalation β€” INR subtherapeutic:** Reassess adherence/interactions + thrombosis risk per indication - **Procedure or neuraxial in 48–72h** β†’ **reassess anticoagulant plan** β€” DOAC hold windows **β‰ ** warfarin; document last dose time - **Interacting drug added or stopped** β†’ **recheck INR (warfarin) or reassess bleed risk / renal (DOAC)** within **48–72h** - If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)
  • Hold if:
    - β€’ **INR 4.5–10, no bleed** β†’ **hold** Β± **low-dose vitamin K** (selected patients, per guideline)
    - **Bleeding, unexplained Hb drop, thunderclap headache, or focal neuro signs** β†’ **hold** anticoagulant + escalate per bleed protocol

Overdose / toxicity

Clinical Picture

β€’ **No bleed:** Supratherapeutic **INR** β†’ **hold Β± vitamin K** per INR-based guideline table β€” **not** PCC β€’ **Minor bleed:** Hold warfarin β†’ local control β†’ **vitamin K PO/SQ** per protocol β†’ recheck INR β€’ **Major bleed / ICH:** **4F-PCC + IV vitamin K immediately** (paired) + **ICU** β€” **vitamin K alone too slow** as sole acute therapy

Immediate Actions

β€’ **No bleed:** **Hold/adjust** warfarin β†’ **INR 24–48h** β†’ **vitamin K only if INR table indicates** β†’ **no PCC** β€’ **Minor bleed:** **Hold** β†’ hemostasis β†’ **vitamin K** per severity β†’ monitor INR β€’ **Major bleed / ICH:** **4F-PCC + IV vitamin K immediately** (protocol doses) β†’ **ICU** as indicated β†’ repeat INR per guideline

Antidote

**Antidote / reversal drugs:** **Major bleed** β†’ **4F-PCC + IV vitamin K** (together). **No bleed** β†’ **vitamin K by INR tier** β€” avoid unnecessary full-dose K for mild elevations

Decontamination

β€’ **Rare acute massive ingestion:** Charcoal early β€’ **Typical supratherapeutic INR:** Therapeutic adjustment β€” not toxicology-first pathway

Escalation

β€’ **Major:** **ICU**; neurosurgery if ICH; MTP if indicated β€’ **HD:** Does **not** remove warfarin

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

**INR is everything** β€” dose follows lab, not habit. β†’ Interaction check on **every** new prescription. β†’ Bridge only when guideline says so.

Clinical pearls

Reversal: life-threatening bleed β†’ PCC + IV vitamin K; minor elevation β†’ PO vitamin K doses per guideline. Diet: consistency > elimination of greens. *Anticoagulation (all agents):* **A/B/C bleed tiers** β€” no bleed (hold/adjust) vs minor (hold/protocol) vs major (reversal + ICU/heme). **Warfarin:** high INR without bleed **β‰ ** major-bleed pathway; **PCC + IV K** for life-threatening bleed. **Bridging:** warfarin **slow on/off**; **parenteral overlap** when indicated for acute VTE; **no routine bridge** low-risk AF; **DOAC↔warfarin** table-specific. **Neuraxial:** explicit **last-dose β†’ procedure** documentation. Never extend therapy without indication review.

Anticoagulant safety

  • INR monitoring adherence
  • Fall and bleed risk counseling
  • Medication reconciliation every visit

Pharmacy Tool

Preparation Calculator

Warfarin 1 mg/mL oral suspension

suspension Β· oral

Acknowledge the statements above to unlock volume scaling and ingredient quantities.

Pharmacokinetics

Racemic; highly protein bound; S-enantiomer more potent; onset 24–72h for full effect; long offset after stop.

Mechanism of action

Inhibits vitamin K epoxide reductase β†’ ↓ II, VII, IX, X, protein C/S synthesis.

Common brand names

Saudi Arabia

Coumadin, Marevan, Warfarin

Global

Jantoven, (placeholder β€” verify local prefilled syringe / vial)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • Reversal agents (PCC, andexanet, idarucizumab) availability and dosing vary by hospital β€” follow local protocol.
  • Perioperative interruption and bridging are **indication-specific** β€” do not copy warfarin rules onto DOACs blindly.
  • Switching between anticoagulants requires manufacturer tables + pharmacy to avoid under- or over-anticoagulation.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • CHEST / ACCP antithrombotic guidance (indication-specific)
  • ESC / AHA stroke and anticoagulation guidelines where applicable
  • ASH β€” HIT and VTE resources
  • FDA / SFDA product labeling
  • Institutional anticoagulation service / formulary
  • CHEST / ACCP antithrombotic guidance (indication-specific)
  • ESC / AHA stroke and anticoagulation guidelines where applicable
  • ASH β€” HIT and VTE resources
  • FDA / SFDA product labeling
  • Institutional anticoagulation service / formulary

Do not miss

  • Document indication, target intensity, and planned duration in the chart
  • Reassess renal/hepatic function after AKI, dehydration, or new interacting medications
  • **Reversal algorithm:** **(1) INR elevated, no bleed** β†’ **hold** (Β± dose reduction) + **vitamin K only per INR-based guideline table** β€” **no PCC**. **(2) Major / life-threatening bleed or ICH** β†’ **4F-PCC + IV vitamin K immediately** per protocol + **ICU** β€” **vitamin K alone too slow** as sole acute therapy.
  • **Heparin β†’ warfarin overlap:** Continue **parenteral heparin β‰₯5 days** AND until INR **therapeutic for β‰₯24h** on warfarin (indication-specific targets) β€” **do not stop heparin early** on first therapeutic INR alone.
  • **Duplicate / stack:** Warfarin + antiplatelet + DOAC/LMWH β†’ audit on every admission and clinic visit.
  • **Bridging errors:** Do not bridge low-risk AF; **DOAC peri-op rules β‰  warfarin**.
  • **Peri-procedure:** Restart only when surgical hemostasis secure; **neuraxial** timing per ASRA + documented last dose.
  • Sudden headache or neuro deficit on warfarin β†’ **ICH** until proven otherwise.
  • INR >10 without bleed β†’ still high-risk β€” treat per protocol.
  • **Bridging & transitions (factory scaffold):**
  • **Warfarin** has **delayed onset/offset** β€” do not expect immediate effect or rapid washout like DOACs.
  • **Acute thrombosis** may require **parenteral overlap** when starting/overlapping warfarin or per label β€” **indication-specific**.
  • **Low-risk AF peri-procedure:** **do NOT routinely bridge** β€” stratify thromboembolic risk per guideline/CHEST-style tables.
  • **DOAC ↔ warfarin** switches are **indication- and table-specific** β€” pharmacy + label (valve, APS, renal).
  • **Neuraxial / high-bleed procedure:** document **last dose**, **ASRA/institutional** windows, **restart** only when hemostasis secure.
  • INR monitoring adherence
  • Fall and bleed risk counseling
  • Medication reconciliation every visit